Feliz C tablets 10mg No. 30

Feliz C is prescribed for the treatment of major depressive episodes, panic disorders with or without agoraphobia, social anxiety disorders (social phobia), generalized anxiety disorders, and obsessive-compulsive disorders.

Composition

Contraindication

Hypersensitivity to escitalopram or to any of the other ingredients of the drug; concomitant treatment with non-selective, irreversible monoamine oxidase inhibitors (MAOIs), as there is a risk of developing serotonin syndrome, manifested by agitation, tremor, hyperthermia. QT prolongation or congenital long QT syndrome. Concomitant use with drugs that prolong the QT interval and pimozide.

Method of application

Usually prescribed 10 mg once a day. Depending on the individual sensitivity of the patient, the daily dose can be increased to a maximum of 20 mg.

The antidepressant effect usually occurs after 2-4 weeks. After the symptoms disappear, treatment should be continued for at least 6 months to consolidate the effect.

Application features

Pregnant women

Escitalopram is contraindicated in pregnant women unless the need for the drug has been clearly demonstrated after careful consideration of the risks and benefits. Careful observation of newborns whose mothers have taken escitalopram during pregnancy, especially in the third trimester, is recommended. Abrupt withdrawal of the drug during pregnancy should be avoided.

Children

Antidepressants should not be prescribed to treat children.

Drivers

Although escitalopram does not affect intellectual or psychomotor functioning, any psychoactive drug may impair skills or the ability to think rationally. Patients should be warned of the potential risk of impairment in driving or operating machinery.

Overdose

Escitalopram overdose is manifested mainly by symptoms from the central nervous system (ranging from dizziness, tremor and agitation to rare cases of serotonin syndrome, seizures and coma), the gastrointestinal system (nausea/vomiting), the cardiovascular system (arterial hypotension, tachycardia, QT prolongation, arrhythmia) and electrolyte imbalance (hypokalemia, hyponatremia).

Adverse reactions

Adverse reactions are most often observed during the first or second week of treatment and usually their frequency and intensity gradually decrease with continued treatment.

Interaction

Serious reactions have been reported in patients taking SSRIs in combination with a non-selective irreversible MAOI and in patients who have recently stopped treatment with an SSRI and started taking an MAOI. In some cases, serotonin syndrome has developed. The combination of escitalopram with non-selective irreversible MAOIs is contraindicated. Treatment with escitalopram should be initiated 14 days after discontinuation of the irreversible MAOI. Treatment with non-selective irreversible MAOIs should be initiated no earlier than 7 days after discontinuation of escitalopram.

Storage conditions

Store at a temperature not exceeding 25 °C in the original packaging. Keep out of the reach of children.

Shelf life - 3 years.